Recent progress in the repurposing of drugs/molecules for the management of COVID-19

Divakar Sharma, Adinarayana Kunamneni

Research output: Contribution to journalReview articlepeer-review


Introduction: In the current scenario, COVID-19 is a clinical and public health problem globally. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the causative agent, emerged in China and continuously spreading across the globe. Until now, no efficient therapeutics have been approved, which combat COVID-19. FDA approved broad-spectrum drugs/molecules could be repurposed against the COVID-19 and are under clinical trials, if the outcome of these trials proves positive, it could be used to manage COVID-19 pandemic. Areas covered: This article reviews the FDA approved drugs/molecules which could be repurposed in the combination or single to combat the COVID-19. Expert opinion: In this focused review, we suggested the repurposing of the pathogen-centric, host-centric, dual sword (act as pathogen-centric as well as host-centric), and the combinatorial (pathogen and host-centric) drugs against COVID-19 patients. These drugs singly or in combination could be effective for the management of COVID-19.

Original languageEnglish (US)
Pages (from-to)889-897
Number of pages9
JournalExpert Review of Anti-Infective Therapy
Issue number7
StatePublished - 2021


  • COVID-19
  • SARS-CoV-2
  • host-centric
  • pathogen-centric
  • repurposing of drugs

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Recent progress in the repurposing of drugs/molecules for the management of COVID-19'. Together they form a unique fingerprint.

Cite this